Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Aspart (NovoLog) vs Insulin Glargine (Lantus)
An educational, source-based comparison of Insulin Aspart (NovoLog) and Insulin Glargine (Lantus) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant insulin analog with proline→aspartic acid at B28, reducing hexamer stability for rapid absorption and prandial glucose control.
- Prandial coverage
- CSII pump therapy
- Inpatient glycemic management
- • FDA-approved.
- • Hypoglycemia is the principal risk.
Long-acting basal insulin analog for type 1 and type 2 diabetes.
Recombinant human insulin analog with two arginine residues added to the B-chain and asparagine→glycine at A21, forming microprecipitates at injection site for ~24-hour glucose-lowering activity via insulin receptor activation.
- Type 1 diabetes basal coverage
- Type 2 diabetes basal insulin therapy
- Gestational diabetes
- • FDA-approved.
- • Hypoglycemia and weight gain are primary risks.
- • Do not mix with other insulins.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Insulin Aspart (NovoLog) | Aspart vs regular insulin postprandial control | Diabetes Care | 2000 | Better postprandial glucose with similar overall safety. |
| Insulin Glargine (Lantus) | Treat-to-target insulin glargine trials | Diabetes Care | 2003 | Established efficacy and lower nocturnal hypoglycemia vs NPH insulin. |
Side-effect & safety grid
- FDA-approved.
- Hypoglycemia is the principal risk.
- FDA-approved.
- Hypoglycemia and weight gain are primary risks.
- Do not mix with other insulins.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Insulin Aspart (NovoLog) vs Insulin Glargine (Lantus) — Key differences
- Class: Insulin Aspart (NovoLog) is classified as Insulin Analog · Endocrine, while Insulin Glargine (Lantus) is Insulin Analog · Endocrine.
- Primary research focus: Insulin Aspart (NovoLog) — prandial coverage; Insulin Glargine (Lantus) — type 1 diabetes basal coverage.
- Tag: FDA-Approved · Diabetes vs FDA-Approved · Diabetes.
Insulin Aspart (NovoLog) — Frequently Asked Questions
Insulin aspart vs lispro — which has faster onset?+
Standard-formulation insulin aspart (Novolog) and insulin lispro (Humalog) both have an onset of ~10–15 minutes and comparable time-to-peak. Ultra-rapid formulations (faster aspart / Fiasp and lispro-aabc / Lyumjev) have slightly earlier appearance in circulation but similar clinical outcomes on postprandial glucose.
Insulin Glargine (Lantus) — Frequently Asked Questions
Lantus vs Humalog — what is the difference?+
Lantus (insulin glargine U-100) is a long-acting basal insulin analogue providing a relatively flat 24-hour glucose-lowering profile from a once-daily subcutaneous injection; it is used to cover fasting and between-meal glucose. Humalog (insulin lispro) is a rapid-acting mealtime analogue with an onset of ~15 minutes, peak at ~1 hour, and duration of ~4 hours; it is dosed at meals to cover the postprandial glucose rise. In a basal-bolus regimen the two are used together, not interchangeably.
Lantus vs Novolog — how do they differ?+
Lantus (insulin glargine) is a long-acting basal insulin; Novolog (insulin aspart) is a rapid-acting mealtime insulin. They serve different roles in a basal-bolus regimen — Lantus provides 24-hour background coverage, Novolog covers meals. Novolog is pharmacokinetically similar to Humalog (lispro).
Insulin glargine vs lispro — can they be mixed in the same syringe?+
No. Insulin glargine (Lantus) must not be mixed with any other insulin, including rapid-acting analogues such as lispro (Humalog) or aspart (Novolog). Mixing alters the pharmacokinetic profile of glargine and is contraindicated per FDA labeling. Basal-bolus therapy uses separate injections.
Novolog vs Lantus timing — how are they scheduled?+
Lantus (glargine) is typically dosed once daily at the same time each day (morning or bedtime). Novolog (aspart) is dosed within 5–10 minutes of the start of a meal — sometimes immediately after in specific populations. Splitting basal (Lantus) and mealtime (Novolog) coverage is the standard basal-bolus approach.